2018
Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso
Somé A, Bazié T, Zongo I, Yerbanga R, Nikiéma F, Neya C, Taho L, Ouédraogo J. Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso. Parasites & Vectors 2018, 11: 323. PMID: 29843783, PMCID: PMC5975679, DOI: 10.1186/s13071-018-2895-4.Peer-Reviewed Original ResearchConceptsSymptomatic malaria patientsPolymerase chain reactionMalaria patientsAllelic familiesBobo-DioulassoMAD20 allelic familyUrban health centersCause of morbidityMerozoite surface protein 1K1 allelic familySurface protein 1Plasmodium falciparum msp1P. malariaUncomplicated malariaFalciparum infectionResultsA totalHealth centersBlood samplesP. falciparumConclusionsOur studyBlood spotsMalaria parasite populationsAllele frequenciesPatientsBurkina Faso
2016
Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso
Sondo P, Derra K, Nakanabo S, Tarnagda Z, Kazienga A, Zampa O, Valéa I, Sorgho H, Owusu-Dabo E, Ouédraogo J, Guiguemdé T, Tinto H. Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLOS ONE 2016, 11: e0151565. PMID: 27031231, PMCID: PMC4816516, DOI: 10.1371/journal.pone.0151565.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllelesAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsBurkina FasoChildDrug CombinationsEthanolaminesFemaleFluorenesGene FrequencyGenotypeHost-Parasite InteractionsHumansMalaria, FalciparumMaleMembrane Transport ProteinsMiddle AgedMultidrug Resistance-Associated ProteinsMultivariate AnalysisParasitemiaPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsTreatment OutcomeConceptsPfmdr1 allelesTreatment failureArtemether-lumefantrine therapyPfcrt K76TSingle nucleotide polymorphismsRestriction fragment length polymorphism methodFragment length polymorphism methodPotential beneficial effectsLength polymorphism methodArtesunate-AmodiaquineRecurrent parasitaemiaTreatment regimenACT resistanceCombination therapyK76TPfmdr1 geneClinical trialsTreatment outcomesMultivariate analysisDay 0PfcrtMalaria controlBlood spotsBeneficial effectsPolymorphism method
2015
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé A, Coulibaly A, Traore O, Dara N, Kabore M, Thera I, Compaore Y, Sylla M, Nikiema F, Diallo M, Dicko A, Gil J, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Bjorkman A, Ouedraogo J, Sirima S, Djimdé A. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. The Lancet Infectious Diseases 2015, 16: 189-198. PMID: 26601738, PMCID: PMC4726763, DOI: 10.1016/s1473-3099(15)00318-7.Peer-Reviewed Original ResearchConceptsSubstudy analysisFirst episodeFirst treatmentArtemisinin-based combination treatmentDeveloping Countries Clinical Trials PartnershipPrimary safety endpointPyronaridine-artesunate efficacyHistory of feverIncidence of hepatotoxicityAdverse event frequencyExclusion of patientsUK Medical Research CouncilMedical Research CouncilParasitological responseSafety endpointArtemether-lumefantrineMalaria episodesTreat analysisAfrican patientsMalaria treatmentClinical trialsMalaria VentureLaboratory valuesAlanine aminotransferaseHealth facilities
2009
Phylogenetic Analysis of Human Parvovirus B19 Sequences from Eleven Different Countries Confirms the Predominance of Genotype 1 and Suggests the Spread of Genotype 3b
Hübschen J, Mihneva Z, Mentis A, Schneider F, Aboudy Y, Grossman Z, Rudich H, Kasymbekova K, Sarv I, Nedeljkovic J, Tahita M, Tarnagda Z, Ouedraogo J, Gerasimova A, Moskaleva T, Tikhonova N, Chitadze N, Forbi J, Faneye A, Otegbayo J, Charpentier E, Muller C. Phylogenetic Analysis of Human Parvovirus B19 Sequences from Eleven Different Countries Confirms the Predominance of Genotype 1 and Suggests the Spread of Genotype 3b. Journal Of Clinical Microbiology 2009, 47: 3735-3738. PMID: 19741071, PMCID: PMC2772644, DOI: 10.1128/jcm.01201-09.Peer-Reviewed Original Research
2006
Enzyme-linked immunosorbent assay with worm vomit and cercarial secretions of Schistosoma mansoni to detect infections in an endemic focus of Burkina Faso
Bahgat M, Sorgho H, Ouédraogo J, Poda J, Sawadogo L, Ruppel A. Enzyme-linked immunosorbent assay with worm vomit and cercarial secretions of Schistosoma mansoni to detect infections in an endemic focus of Burkina Faso. Journal Of Helminthology 2006, 80: 19-23. PMID: 16469168, DOI: 10.1079/joh2005312.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayDetectable eggsCercarial secretionsS. mansoni endemic areasKato-Katz thick smearsSchistosoma mansoniParasitological stool examinationEnzyme-linked immunosorbentHigh diagnostic sensitivityAdult Schistosoma mansoniStool examinationIgG reactivityStool specimensThick smearsOlder individualsEndemic fociDiagnostic sensitivityImmunosorbent assayOptical density valuesPositive reactionBurkina FasoVomitRespective percentagesMansoniSecretion
2005
Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso.
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M, Ouedraogo J, ROSENTHAL P. Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. American Journal Of Tropical Medicine And Hygiene 2005, 73: 826-32. PMID: 16282288, DOI: 10.4269/ajtmh.2005.73.826.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaFalciparum malariaTreatment failureEfficacy of amodiaquineEarly treatment failureSerious adverse eventsPatients 6 monthsRisk of recrudescenceEfficacy outcomesUncomplicated malariaAdverse eventsWHO criteriaAvailable therapiesCombination therapyAntimalarial therapyClinical failureNew infectionsAmodiaquineBurkina FasoTherapyRelative efficacyMalariaBobo-DioulassoPyrimethamineTrials
2001
Preliminary study of cutaneous leishmaniasis in the town of Ouagadougou from 1996 to 1998.
Traoré K, Sawadogo N, Traoré A, Ouedraogo J, Traoré K, Guiguemdé T. Preliminary study of cutaneous leishmaniasis in the town of Ouagadougou from 1996 to 1998. Bulletin De La Société De Pathologie Exotique 2001, 94: 52-5. PMID: 11346985.Peer-Reviewed Original ResearchConceptsCutaneous leishmaniasisClinical formsHealth centersMonths of progressionAge of patientsFrequent clinical formPublic Health CenterDifferent clinical formsSite of infectionHealth care staffReports of casesProtocol therapyProspective studyRetrospective studyMean ageLocal etiologyInferior limbHigh incidenceCommon locationPatientsCare staffClinical casesCase managementDecisional algorithmLeishmaniasis
1997
Esquisse d'une méthode d'estimation du coût économique chiffré des accès palustres: application à une zone rurale au Burkina Faso (Afrique de l'Ouest)
Guiguemdé T, Coulibaly N, Coulibaly S, Ouedraogo J, Gbary A. Esquisse d'une méthode d'estimation du coût économique chiffré des accès palustres: application à une zone rurale au Burkina Faso (Afrique de l'Ouest). Tropical Medicine And International Health 1997, 2: 646-653. PMID: 9289349, DOI: 10.1046/j.1365-3156.1997.d01-351.x.Peer-Reviewed Original ResearchConceptsDuration of illnessIndirect costsDirect costsHealth center clientsCosts of malariaAccount direct costsAge of subjectsMost patientsConsultation feesAverage durationDegree of invalidityMicroscopic examinationBurkina FasoCenter clientsIllnessMalariaAdultsChildrenYearsDurationMedicationsRural areasPatientsMalaria morbidity in adults living in urban Burkina Faso.
Guiguemde T, Ouedraogo I, Ouedraogo J, Coulibaly S, Gbary A. Malaria morbidity in adults living in urban Burkina Faso. Medecine Tropicale 1997, 57: 165-8. PMID: 9304011.Peer-Reviewed Original ResearchConceptsLevel of immunizationPoor positive predictive valueSerious public health problemMain clinical featuresPublic health problemDiagnosis of malariaBobo-DioulassoPositive predictive valueParasitic indexMedian parasitemiaClinical featuresClinical symptomsMalaria morbidityProspective studyParasitological featuresParasite densityHigh incidencePlace of residencePredictive valueHealth problemsEndemic malariaMalariaUrban Burkina FasoAdultsMicroscopic examination
1996
Selected P. falciparum specific immune responses are maintained in AIDS adults in Burkina Faso
MIGOT F, OUEDRAOGO J, DIALLO J, ZAMPAN H, DUBOIS B, SCOTT‐FINNIGAN T, .SANOU P, DELORON P. Selected P. falciparum specific immune responses are maintained in AIDS adults in Burkina Faso. Parasite Immunology 1996, 18: 333-339. PMID: 9229386, DOI: 10.1046/j.1365-3024.1996.d01-116.x.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnimalsAntigens, ProtozoanBurkina FasoCase-Control StudiesCD4 Lymphocyte CountCD4-Positive T-LymphocytesCytokinesHIV-1HumansIn Vitro TechniquesInterferon-gammaInterleukin-2Interleukin-4Lymphocyte ActivationMalaria, FalciparumMiddle AgedPlasmodium falciparumConceptsImmune responseSchizont extractCytokine productionHIV-1Healthy subjectsHIV-1-positive subjectsSpecific human immune responsesCrude schizont extractNegative healthy subjectsPlasmodium falciparum malariaHIV-1 infectionIL-4 productionSpecific immune responseHuman immune responseWhole blood culturesIL-2 productionPresence of PHAMerozoite surface proteinAIDS adultsLymphocyte subsetsFalciparum malariaClinical AIDSAIDS patientsPositive subjectsMalarial antigens
1991
Preliminary epidemiological study of dracunculosis in the southwest of Burkina Faso.
Gbary A, Ouedraogo J, Guiguemde T. Preliminary epidemiological study of dracunculosis in the southwest of Burkina Faso. Medecine Tropicale 1991, 51: 263-7. PMID: 1834910.Peer-Reviewed Original Research